PMID- 35459242
OWN - NLM
STAT- MEDLINE
DCOM- 20220426
LR  - 20220716
IS  - 1743-422X (Electronic)
IS  - 1743-422X (Linking)
VI  - 19
IP  - 1
DP  - 2022 Apr 22
TI  - A novel cocktail therapy based on quintuplet combination of oncolytic herpes 
      simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, 
      and IL-7 x CCL19 results in enhanced antitumor efficacy.
PG  - 74
LID - 10.1186/s12985-022-01795-1 [doi]
LID - 74
AB  - BACKGROUND: Selectively replicating herpes simplex virus-2 (HSV-2) vector is a 
      promising treatment for cancer therapy. The insertion of multiple transgenes into 
      the viral genome has been performed to improve its oncolytic activity. METHODS: 
      Herein, we simultaneously constructed five "armed" oncolytic viruses (OVs), 
      designated oHSV2-IL12, -IL15, GM-CSF, -PD1v, and IL7 x CCL19. These OVs delete 
      the ICP34.5 and ICP47 genes with the insertion of transgenes into the deleted 
      ICP34.5 locus. The anti-tumor efficacy in vivo was tested in the syngeneic 4T1 
      and CT26 tumor-bearing mice model. RESULTS: The OVs showed comparable oncolytic 
      capability in vitro. The combination therapy of oHSV2-IL12, -IL15, GM-CSF, -PD1v, 
      and IL7 x CCL19 exhibited the highest tumor inhibition efficacy compared with the 
      treatment of single OV or two OVs combination. CONCLUSIONS: The OVs armed with 
      different transgenes combination therapy also named 5-valent oHSV2 (also called 
      cocktail therapy) might be an effective therapeutic strategy for solid tumors.
CI  - (c) 2022. The Author(s).
FAU - Hu, Han
AU  - Hu H
AUID- ORCID: 0000-0002-8188-6143
AD  - National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key 
      Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial 
      Cooperative Innovation Center of Industrial Fermentation, College of 
      Bioengineering, Hubei University of Technology, Wuhan, China.
FAU - Zhang, Siqi
AU  - Zhang S
AD  - Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, China.
FAU - Cai, Linkang
AU  - Cai L
AD  - Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, China.
FAU - Duan, Haixiao
AU  - Duan H
AD  - National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key 
      Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial 
      Cooperative Innovation Center of Industrial Fermentation, College of 
      Bioengineering, Hubei University of Technology, Wuhan, China.
FAU - Li, Yuying
AU  - Li Y
AD  - Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, China.
FAU - Yang, Junhan
AU  - Yang J
AD  - National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key 
      Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial 
      Cooperative Innovation Center of Industrial Fermentation, College of 
      Bioengineering, Hubei University of Technology, Wuhan, China.
FAU - Wang, Yang
AU  - Wang Y
AD  - National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key 
      Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial 
      Cooperative Innovation Center of Industrial Fermentation, College of 
      Bioengineering, Hubei University of Technology, Wuhan, China.
FAU - Liu, Biao
AU  - Liu B
AD  - National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key 
      Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial 
      Cooperative Innovation Center of Industrial Fermentation, College of 
      Bioengineering, Hubei University of Technology, Wuhan, China.
FAU - Dong, Shuang
AU  - Dong S
AD  - Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan, China.
FAU - Fang, Zhizheng
AU  - Fang Z
AD  - Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, China.
FAU - Liu, Binlei
AU  - Liu B
AD  - National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key 
      Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial 
      Cooperative Innovation Center of Industrial Fermentation, College of 
      Bioengineering, Hubei University of Technology, Wuhan, China. liubl@hbut.edu.cn.
AD  - Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, China. liubl@hbut.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220422
PL  - England
TA  - Virol J
JT  - Virology journal
JID - 101231645
RN  - 0 (Interleukin-15)
RN  - 0 (Interleukin-7)
RN  - 187348-17-0 (Interleukin-12)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - Genetic Vectors/genetics
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/genetics/therapeutic use
MH  - Herpesvirus 2, Human/genetics
MH  - Interleukin-12/genetics
MH  - Interleukin-15/genetics
MH  - Interleukin-7/genetics
MH  - Mice
MH  - *Neoplasms/drug therapy
MH  - *Oncolytic Virotherapy/methods
MH  - *Oncolytic Viruses/genetics
PMC - PMC9034647
OTO - NOTNLM
OT  - 4T1
OT  - CT26
OT  - Combined therapy
OT  - Oncolytic herpes simplex virus
COIS- SZ, LC, YL, ZF, BL are employed by Wuhan Binhui Biopharmaceutical Co., Ltd. The 
      authors would like to state clearly that there are no commercial conflicts with 
      this work.
EDAT- 2022/04/24 06:00
MHDA- 2022/04/27 06:00
PMCR- 2022/04/22
CRDT- 2022/04/23 05:12
PHST- 2021/08/26 00:00 [received]
PHST- 2022/04/03 00:00 [accepted]
PHST- 2022/04/23 05:12 [entrez]
PHST- 2022/04/24 06:00 [pubmed]
PHST- 2022/04/27 06:00 [medline]
PHST- 2022/04/22 00:00 [pmc-release]
AID - 10.1186/s12985-022-01795-1 [pii]
AID - 1795 [pii]
AID - 10.1186/s12985-022-01795-1 [doi]
PST - epublish
SO  - Virol J. 2022 Apr 22;19(1):74. doi: 10.1186/s12985-022-01795-1.